Sevoflurane augmentation in treatment-resistant depression: a clinical case study-Reference-Cited by-同舟云学术

Sevoflurane augmentation in treatment-resistant depression: a clinical case study

Published:2020-01 Issue: Volume:10 Page:204512532095712
ISSN:2045-1253
Container-title:Therapeutic Advances in Psychopharmacology
language:en
Short-container-title:Therapeutic Advances in Psychopharmacology

Author:

Wang Shikai¹²,Cheng Shanfei²,Feng Min²,Guo Ping²,Qian Mincai²,Shen Xinhua²,Chen Runsen³^ORCID,Wang Gang⁴

Affiliation:

1. National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, and Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China

2. The 3rd Hospital in Huzhou Municipal, Zhejiang, China

3. The National Clinical Research Centre for Mental Disorders, Beijing Key Laboratory of Mental Disorders and Advanced Innovation Centre for Human Brain Protection, Beijing Anding Hospital, Capital Medical University, Beijing, China

4. National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, and Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088, China

Abstract

Compared with other inhaled anaesthetics, sevoflurane has a faster onset and offset, causes less irritation to the mucous membranes, and has a better safety profile. These characteristics warrant investigating the effect of sevoflurane in depression. In this Case Report, we describe that sevoflurane treatment was feasible and well tolerated by a patient with treatment-resistant depression (TRD). Sevoflurane had rapid and durable antidepressant effects, with few adverse effects. Moreover, the patient showed significant improvements in neurocognitive measurements. Our preliminary results suggest that further clinical trials are needed to determine the independent efficacy and safety of sevoflurane in patients with TRD.

Funder

National Science and Technology Major Project for IND

National Key Technology Research and Development Program of the Ministry of Science and Technology of China

Huzhou applied research project

Beijing Municipal Science &Tech Commission

National Key Research and Development Program of China

Capital’s Science and Technology Talent Project

Capital’s Funds for Health Improvement and Research

Publisher

SAGE Publications

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Psychology (miscellaneous)